Project Grant R44DK142244
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$325K
Awardee
Syntis Bio Inc. (NG1VDVGBHC87)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,561,974 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Syntis Bio Inc. in Dorchester, MA. The goal of this Fast-Track SBIR project is to develop an oral pill that blocks nutrient absorption in the duodenum, mimicking the effects of gastric bypass surgery for obesity treatment. Syntis Bio will optimize their Gastrointestinal Synthetic...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $299,648 to Cometa Therapeutics Inc. to conduct enabling studies for CMT-101, a novel gene therapy for Glycogen Storage Disease 1B (GSD-1B). The funding will support dose-finding, biodistribution, and toxicology studies to advance CMT-101, an AAV-based gene therapy, towards an...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to demonstrate the efficacy of using hydrodynamic gene delivery to provide lifelong correction of Hereditary Tyrosinemia Type 1 (HT1) and other monogenic liver diseases. The $881,961 award to Hydrogene Therapeutics Inc. will fund a Fast-Track project to optimize a non-viral vector system...
This Project Grant award of $613,558 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports Genetobe Inc., a Michigan-based biotechnology company, in developing novel, selective sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor compounds as an adjunctive therapy for cystic fibrosis (CF) associated metabolic disorders, including CF-associated liver disease and CF-related diabetes. The...
The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases awarded $3.6 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Anagram Therapeutics Inc. to develop a novel pancreatic enzyme replacement therapy. Specifically, Anagram will engineer lipase enzymes for improved stability against low pH and proteolytic degradation. This will allow for effective digestion of fats in both the stomach and small...
This Project Grant award, valued at $195,625.00 and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), will support preclinical studies to evaluate the long-term efficacy of AAV9-based gene therapy for classic galactosemia (CG) in a GALT-null rat model. The goal is to test whether a single intravenous dose of scAAV9-hGALT can prevent representative long-term complications associated with CG,...
This federal Project Grant award of $698,074 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports the development of a platform technology for targeted oral delivery of therapeutic proteins to the intestines. The goal is to enable the delivery of biological agents, such as anti-TNFα therapies, directly to the site of inflammation in patients with ulcerative colitis, rather than requiring...
The National Institute of Child Health and Human Development (NICHD) awarded a $295,923 Project Grant to Biostrategies LC under the Child Health and Human Development Extramural Research program (CFDA 93.865). The purpose of the award is to develop a "delivery-enhanced" gene therapy drug comprising an RTB:GALNS fusion protein for treating the rare metabolic disorder Mucopolysaccharidosis Type IVA (Morquio A Syndrome). The key objectives are to: 1) optimize the RTB:GALNS construct for...